India Business News: Pharma giant Novartis AG is conducting a strategic review of Novartis India, including its shareholding in the BSE listed company. The review's outcom
There can be no assurance that the strategic review of Novartis India Ltd will be completed in 2024, or that the outcome would result in the implementation of any transaction, it said.
The report comes a day after Novartis AG announced a strategic review of its India arm. The strategic review, the firm, said includes an assessment of the 70.68 per cent shareholding of Novartis AG in the company.
Novartis India, a listed entiry, is set to undergo an assessment encompassing various aspects, including its parent Novartis AG s 70.68 percent shareholding.